Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

StatusUnknown
PhasePhase 2
SponsorHao Zeng
Started

Record status This record was last updated July 26, 2024 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jul 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hao Zeng
2 trials monitored
See all monitored trials
Kidney Cancer
891 trials monitored
See 72 trials at risk
This Phase II trial assesses Vorolanib and Sintilimab for advanced renal cell carcinoma after previous therapy failure. Participants receive the treatment until disease progression, intolerable side effects, death, or withdrawal. The primary endpoint is progression-free survival (PFS).
Trial Details
NCT Number NCT06523049
Lead Sponsor Hao Zeng
Conditions
(from sponsor)		 Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy
Related terms Carcinoma, Renal Cell
Enrollment 67 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov